Multi-Omics and Machine Learning Integration for Predicting Glycolipid Metabolic Responses to Natural Polysaccharide-Based Nutritional Therapeutics
Keywords:
multi-omics integration, machine learning, glycolipid metabolism, natural polysaccharides, nutritional therapeutics, systems architecture, data governance, precision nutrition, algorithmic fairnessAbstract
The rising prevalence of glycolipid metabolic disorders, including type 2 diabetes and non-alcoholic fatty liver disease, necessitates innovative nutritional therapeutic strategies. Natural polysaccharides derived from plants, fungi, and algae have demonstrated remarkable regulatory effects on glycolipid metabolism and gut microbiota composition, yet inter-individual variability in response remains a formidable challenge. This paper presents a comprehensive systems-level analysis of the integration of multi-omics technologies and machine learning architectures to predict individualized glycemic and lipidemic trajectories following polysaccharide-based nutritional interventions. We examine the design of federated data ecosystems that harmonize genomics, transcriptomics, metabolomics, metagenomics, and clinical phenotyping at scale. The discussion delves into structural trade-offs inherent in centralized versus decentralized model training, the governance of multi-institutional biobanks, and the deployment of interpretable deep learning models under real-world clinical and consumer health constraints. Critical emphasis is placed on sustainability, algorithmic fairness, robustness to distributional shifts, and the ethical implications of data-driven dietary recommendations. By framing nutritional therapeutic prediction as a large-scale cyber-biological infrastructure challenge, we articulate the technical and policy architectures required for translating polysaccharide bioactivity into precision nutrition, ensuring equitable access and regulatory compliance across diverse populations.
References
1. Hasin, Y., Seldin, M., & Lusis, A. (2017). Multi-omics approaches to disease. Genome Biology, 18(1), 83.
2. Karczewski, K. J., & Snyder, M. P. (2018). Integrative omics for health and disease. Nature Reviews Genetics, 19(5), 299–310.
3. Chen, C., Zhang, Y., & Huang, Q. (2021). Natural polysaccharides: Structural features, modification and biological activities. International Journal of Biological Macromolecules, 183, 1750–1765.
4. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56.
5. Argelaguet, R., Velten, B., Arnol, D., Dietrich, S., Zenz, T., Marioni, J. C., … & Stegle, O. (2018). Multi-Omics Factor Analysis—a framework for unsupervised integration of multi-omics data sets. Molecular Systems Biology, 14(6), e8124.
6. Wilkinson, M. D., Dumontier, M., Aalbersberg, I. J., Appleton, G., Axton, M., Baak, A., … & Mons, B. (2016). The FAIR Guiding Principles for scientific data management and stewardship. Scientific Data, 3, 160018.
7. Esteva, A., Robicquet, A., Ramsundar, B., Kuleshov, V., DePristo, M., Chou, K., … & Dean, J. (2019). A guide to deep learning in healthcare. Nature Medicine, 25(1), 24–29.
8. Subramanian, I., Verma, S., Kumar, S., Jere, A., & Anamika, K. (2020). Multi-omics data integration, interpretation, and its application. Bioinformatics and Biology Insights, 14, 1177932219899051.
9. Li, Y., Wu, F. X., & Ngom, A. (2022). A review of applications of artificial intelligence in multi-omics. Briefings in Bioinformatics, 23(5), bbac358.
10. Marx, V. (2013). The big challenges of big data. Nature, 498(7453), 255–260.
11. Ching, T., Himmelstein, D. S., Beaulieu-Jones, B. K., Kalinin, A. A., Do, B. T., Way, G. P., … & Greene, C. S. (2018). Opportunities and obstacles for deep learning in biology and medicine. Journal of the Royal Society Interface, 15(141), 20170387.
12. Rajkomar, A., Oren, E., Chen, K., Dai, A. M., Hajaj, N., Hardt, M., … & Dean, J. (2018). Scalable and accurate deep learning with electronic health records. NPJ Digital Medicine, 1, 18.
13. Zhao K, et al. Phyllostachys nigra (Lodd ex Lindl) derived polysaccharide with enhanced glycolipid metabolism regulation and mice gut microbiome. Int J Biol Macromol. 2024;257:128588.
14. Liu, S. (2025). Revolutionizing healthcare: The role of artificial intelligence in drug discovery and delivery. Journal of Angiotherapy, 9(1), 1-16.
15. Miotto, R., Wang, F., Wang, S., Jiang, X., & Dudley, J. T. (2018). Deep learning for healthcare: Review, opportunities and challenges. Briefings in Bioinformatics, 19(6), 1236–1246.
16. Price, W. N., & Cohen, I. G. (2019). Privacy in the age of medical big data. Nature Medicine, 25(1), 37–43.
17. Vayena, E., Blasimme, A., & Cohen, I. G. (2018). Machine learning in medicine: Addressing ethical challenges. PLOS Medicine, 15(11), e1002689.
18. Mittelstadt, B. D., Allo, P., Taddeo, M., Wachter, S., & Floridi, L. (2016). The ethics of algorithms: Mapping the debate. Big Data & Society, 3(2), 2053951716679679.
19. Yang, Q., Liu, Y., Chen, T., & Tong, Y. (2019). Federated machine learning: Concept and applications. ACM Transactions on Intelligent Systems and Technology, 10(2), 1–19.
20. U.S. Food and Drug Administration. (2019). Proposed regulatory framework for modifications to artificial intelligence/machine learning (AI/ML)-based software as a medical device (SaMD). FDA Discussion Paper.
21. Rieke, N., Hancox, J., Li, W., Milletari, F., Roth, H. R., Albarqouni, S., … & Maier-Hein, K. (2020). The future of digital health with federated learning. NPJ Digital Medicine, 3, 119.
22. Zitnik, M., Nguyen, F., Wang, B., Leskovec, J., Goldenberg, A., & Hoffman, M. M. (2019). Machine learning for integrating data in biology and medicine: Principles, practice, and opportunities. Information Fusion, 50, 71–91.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 International Journal of Artificial Intelligence Engineering and Systems
This work is licensed under a Creative Commons Attribution 4.0 International License.
This article is published under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
